文献速递流行病学与生物统计临床试验与 GCP

慢性病随机对照试验中的预随机导入期:一项方法学研究

Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study.
PubMed 文献 · J Clin Epidemiol · 2020-09-28

该研究系统综述了2011至2016年四本高影响医学期刊中慢性病药物平行随机对照试验的预随机导入期使用情况。262篇合格稿件中48篇(18.3%)报告了导入期,对应42项独特试验;导入期最常见于心血管和糖尿病试验,中位持续28天,中位完成率77.4%。结论认为导入期不常见且报告异质,需改进设计、使用与报告。

要点

  • 慢性病药物RCT中预随机导入期使用不常见,仅48/262篇(18.3%)报告。
  • 导入期最常见于心血管和糖尿病试验,中位持续28天。
  • 导入期主要理由为确保符合入选标准、排除不依从或不耐受者。

核心结论

  • 慢性病药物随机对照试验中预随机导入期不常见,且报告方式异质。
  • 需进一步研究以改进导入期的设计、使用和报告。

研究设计与样本

  • 方法学研究的系统综述,纳入2011至2016年四本最高影响医学期刊的所有随机对照试验。
  • 合格试验为评估成人慢性病药物治疗的平行随机对照试验,最短随访24周。
  • 262篇合格稿件中48篇(18.3%)报告导入期,对应42项独特随机对照试验。

主要发现

  • 导入期最常见于心血管疾病和糖尿病试验。
  • 42项试验中,22项患者接受试验性治疗,15项接受安慰剂,4项两者均用,1项未报告导入期药物。
  • 导入期中位持续时间为28天(Q1:Q3 14:66天)。
  • 导入期中位完成率为77.4%(Q1:Q3 62.2:87.8%)。

关键数值与推荐

  • 纳入导入期的理由包括:确保符合入选标准(18项,42.9%)、排除不依从者(18项,42.9%)、排除治疗不耐受者(15项,35.7%)、随机前标准化治疗(8项,19.0%)。

临床怎么用

  • 解读慢性病药物随机对照试验时需关注是否使用导入期及其对结果外推性的影响。
  • 设计慢性病药物试验时可考虑导入期用于确保入选标准、排除不依从或不耐受者。

局限性

  • 仅纳入四本最高影响医学期刊2011至2016年的随机对照试验,可能不代表其他期刊或时期。
  • 导入期报告异质,部分试验未报告导入期药物等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To systematically review the epidemiology of prerandomized run-in periods in randomized controlled trials (RCTs) of chronic diseases. STUDY DESIGN AND SETTING: Meta-epidemiologic study of all RCTs from the four highest impact medical journals from 2011 to 2016. Eligible trials included parallel RCTs that evaluated pharmacologic therapies in adults with chronic diseases with a minimum follow-up of 24 weeks. RESULTS: Of 262 eligible manuscripts, 48 (18.3%), representing 42 unique RCTs, included run-in periods. Run-in periods were most common in cardiovascular disease and diabetes trials. Of the 42 RCTs, in 22 patients received the experimental therapy, 15 placebo, 4 both (either sequentially or in combination), and one did not report the run-in period drug. The median run-in period duration was 28 days (Q1: Q3 14: 66 days). Reasons for including a run-in period included ensuring eligibility criteria were met (18, 42.9%), excluding participants with nonadherence (18, 42.9%) and intolerances to therapy (15, 35.7%), and to standardize therapy prior to randomization (8, 19.0%). The median run-in completion rate was 77.4% (Q1: Q3 62.2:87.8%). CONCLUSIONS: Run-in periods are uncommon in RCTs of chronic drug treatments and when used, their reporting is heterogeneous. Further research to improve the design, use, and reporting of run-in periods is necessary.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Collister D, Rodrigues JC, Mbuagbaw L, et al. Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study. J Clin Epidemiol. 2020. PMID: 33002638. doi:10.1016/j.jclinepi.2020.09.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。